IDH2 and central nervous system cancer: A total of 345 patients with pathologically confirmed gliomas diagnosed at the First Affiliated Hospital of Xi’an Jiaotong University between October 2019 and October 2024 were retrospectively included, comprising 148 (42.9%) IDH-wild and 197 (57.1%) IDH-mutant.